SLC7A1, solute carrier family 7 member 1, 6541

N. diseases: 46; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0086942
Disease: Rous Sarcoma
Rous Sarcoma 		0.010 Biomarker disease BEFREE To enable human cells to become permissive for ecotropic retrovirus-mediated gene transfer, we have developed a recombinant adeno-associated virus type 2 (AAV) vector containing ecotropic retroviral receptor (ecoR) cDNA under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter (vRSVp-ecoR). 9188645 1997
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.330 AlteredExpression disease BEFREE CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.330 Biomarker disease CTD_human CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.300 Biomarker group CTD_human CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 Biomarker disease BEFREE These findings are the first to implicate a Ca(2+) channel in PCa progression and suggest that CaT1 may be a novel target for therapy. 11401523 2001
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 AlteredExpression disease BEFREE Taken together, these results demonstrate that estrogen-inducible genes such as pS2 can be ERR targets and suggest that pharmacological modulation of ERRalpha activity may have therapeutic value in the treatment of breast cancer. 11559547 2001
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 AlteredExpression disease BEFREE Taken together, these results demonstrate that estrogen-inducible genes such as pS2 can be ERR targets and suggest that pharmacological modulation of ERRalpha activity may have therapeutic value in the treatment of breast cancer. 11559547 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.010 AlteredExpression group BEFREE CaT1 expression correlates with tumor grade in prostate cancer. 11401523 2001
CUI: C1704272
Disease: Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia 		0.010 AlteredExpression disease BEFREE CaT1 mRNA levels were elevated in PCa specimens in comparison to benign prostatic hyperplasia (BPH) specimens and positively correlated with Gleason grade in a PCa series. 11401523 2001
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.330 AlteredExpression disease BEFREE Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues. 12480925 2002
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 AlteredExpression disease BEFREE Finally, we found CaT1 protein to be present at elevated levels in comparison with normal tissues in a series of prostate, breast, thyroid, colon, and ovarian carcinomas, consistent with previous reports of up-regulation of CaT1 mRNA in prostate cancer tissues. 12480925 2002
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.020 AlteredExpression group BEFREE Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. 12480925 2002
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation 		0.020 AlteredExpression phenotype BEFREE In summary, endothelium from fetuses with IUGR exhibit altered L-arginine transport and NO synthesis (L-arginine/NO pathway), reduced expression and activity of hCAT-1 and hCAT-2B and reduced eNOS activity. 12142345 2002
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.010 AlteredExpression disease BEFREE In association with these biochemical indices, we observed a 38% reduction (P<0.05) in the mRNA expression of the cationic amino acid transporter CAT-1 in ventricular myocardial samples from patients with CHF compared with healthy unused donor myocardium, whereas myocardial NOS enzymatic activity and NOS protein were unchanged. 12480822 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.330 Biomarker disease BEFREE In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC). 12584203 2003
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.030 Biomarker disease BEFREE In order to assess the role of CaT1 in generating endogenous store-operated Ca(2+) current (I(SOC)) in the lymph node carcinoma of the prostate (LNCaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of I(SOC). 12584203 2003
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension 		0.030 AlteredExpression disease BEFREE In vivo and in vitro measures of L-arginine transport were substantially reduced in the essential hypertension and positive family history groups compared with the negative family history group; however, no difference was detected in peripheral blood mononuclear cell mRNA or protein expression levels for the cationic amino acid transporter CAT-1. 15569830 2004
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.040 Biomarker group BEFREE Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. 17325243 2007
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.040 GeneticVariation group LHGDN Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. 17325243 2007
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.020 Biomarker phenotype BEFREE Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. 17325243 2007
CUI: C0037284
Disease: Skin lesion
Skin lesion 		0.010 Biomarker group BEFREE In the present study, we characterized the distribution of human cationic amino acid transporters 1 (hCAT1) and 2 (hCAT2) in healthy skin and compared it to psoriatic skin lesions by means of immunohistochemistry. 18172665 2008
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.040 GeneticVariation group BEFREE Mechanistic insights into the link between a polymorphism of the 3'UTR of the SLC7A1 gene and hypertension. 19067360 2009
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension 		0.030 GeneticVariation disease BEFREE We previously identified the polymorphism ss52051869 in the 3'UTR of human SLC7A1, and demonstrated that it might participate in the apparent link between altered endothelial function, decreased L-arginine and nitric oxide (NO) metabolism, and a genetic predisposition to essential hypertension. 19067360 2009
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation 		0.020 AlteredExpression phenotype BEFREE Normal or IUGR HUVEC monolayers were exposed (0-24h) to 5% O(2) (normoxia), and 1 or 2% O(2) (hypoxia). l-Arginine transport and hCAT-1 expression, phosphorylated and total PKCalpha or eNOS protein and mRNA expression were quantified. eNOS involvement was tested using a siRNA against eNOS (eNOS-siRNA) adenovirus. 19501907 2009
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.020 AlteredExpression phenotype BEFREE It is therefore possible that binding of miR-122 to the 3'UTR may cause the depression of gene expression, contributing to the lesser level of SLC7A1 and the endothelial dysfunction seen in hypertensive subjects. 19067360 2009